Beta-Blockers May Exacerbate Psoriasis: Study
- byDoctor News Daily Team
- 04 July, 2025
- 0 Comments
- 0 Mins
Beta-blockers may exacerbate psoriasis, according to a recent study published in the Journal of the European Academy of Dermatology and Venereology: JEADV
De novo psoriasis is described as the occurrence of the disease in those with no personal or family history of the said disease. Psoriasis is notoriously known to be associated with numerous drug use and its exacerbations, including de novo psoriasis in patients with no previous history of psoriasis
Beta-blockers, also spelt β-blockers, are a class of medications that are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack after a first heart attack. Beta-blockers (BB) are known to induce or aggravate psoriasis. However, previous epidemiological studies have reported conflicting results. Considering the correlation between psoriasis and hypertension, it is important to determine whether BB can influence psoriasis development while selecting antihypertensive agents for patients at high risk of psoriasis. This study aims to evaluate the association between BB use and the development of de novo psoriasis in patients with hypertension based on the large-scale database.
Using a nationwide database, the authors identified 105,529 patients without psoriasis who were diagnosed with hypertension. Of these, 17,768 were prescribed beta-blockers in their first antihypertensive regimen
The Results of the study are:
Over 2 years, only 0.4% of patients in the beta-blocker–the exposed group developed psoriasis, which did not differ from those who were not exposed to beta-blockers (also 0.4%).
Thus, the researchers concluded that though there is evidence that beta-blockers may exacerbate psoriasis, it does not appear that they precipitate de novo development of psoriasis.
Reference:
Risk of de novo psoriasis in hypertension patients initially treated with beta-blockers: Nationwide population-based cohort study in Korea by YE Kim, Y Cho, SJ Jo et al. published in Journal of the European Academy of Dermatology and Venereology: JEADV
https://onlinelibrary.wiley.com/doi/10.1111/cen.14640
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Pfizer files lawsuit against Metsera, its Director...
- 02 November, 2025
Health Ministry achieves 3 Guinness World Records...
- 02 November, 2025
Roche gets CE mark for Elecsys Dengue Ag test to d...
- 02 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!